GAITHERSBURG, Md.--(BUSINESS WIRE)--Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into a drug repositioning and development agreement with H. Lundbeck A/S to seek alternative development paths for certain Lundbeck drug candidates. These drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
